Celldex Therapeutics (CLDX) Times Interest Earned (2010 - 2013)
Celldex Therapeutics (CLDX) posted quarterly Times Interest Earned of -$231.96 for Q1 2026, up 38.99% year-over-year from -$166.89 in Q1 2025, and up 98.94% quarter-over-quarter from -$21788.2 in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Times Interest Earned (2010 - 2013) Analysis & Trends
Celldex Therapeutics' Times Interest Earned history runs 16 years deep, the most recent figure standing at -$231.96 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 38.99% year-over-year to -$231.96; the TTM figure through Mar 2026 stood at -$849.07 (up 35.5% YoY), while the FY2025 annual figure was -$0.77, down 25.77% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$231.96, up from -$21788.2 in the prior quarter.
- The five-year high for Times Interest Earned was -$0.09 in Q4 2022, with the low at -$24539.0 in Q3 2025.
- The 5-year median for Times Interest Earned is -$63.01 (2023), against an average of -$3121.0.
- The sharpest annual moves came in 2022 and 2025: Times Interest Earned jumped 96.91% in 2022, then slumped 12434839.7% in 2025.
- Celldex Therapeutics' Times Interest Earned stood at -$0.09 in 2022, then plunged by 53.78% to -$0.14 in 2023, then decreased by 27.8% to -$0.18 in 2024, then plunged by 12434839.7% to -$21788.2 in 2025, then surged by 98.94% to -$231.96 in 2026.
- Business Quant data shows CLDX's Times Interest Earned at -$231.96 in Q1 2026, -$21788.2 in Q4 2025, and -$24539.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | -260.16 |
| Sep 30, 2013 | -1,789.92 |
| Jun 30, 2013 | -35.95 |
| Mar 31, 2013 | -56.13 |
| Dec 31, 2012 | -47.15 |
| Sep 30, 2012 | -38.72 |
| Jun 30, 2012 | -32.82 |
| Mar 31, 2012 | -30.69 |
| Dec 31, 2011 | -28.27 |
| Sep 30, 2011 | -26.21 |
| Jun 30, 2011 | -22.77 |
| Mar 31, 2011 | -19.91 |
| Dec 31, 2010 | 63.03 |
| Sep 30, 2010 | -26.74 |
| Jun 30, 2010 | -27.80 |